Abdera Therapeutics
Abdera Therapeutics is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California, with research operations in Vancouver, British Columbia. It was launched in 2021 out of adMare BioInnovations with AbCellera as a founding partner and has raised roughly $148 million from investors including Versant Ventures, Foresite Capital, Johnson & Johnson Innovation (JJDC), Qiming Venture Partners USA, RTW Investments and venBio. The company engineers precision radiopharmaceuticals for solid tumours on its proprietary Radio Optimized Vector Engineering (ROVEr) platform, which pairs antibody-derived targeting vectors with potent alpha-emitting radioisotopes such as actinium-225. Its lead candidate, ABD-147, targets delta-like ligand 3 (DLL3) and is in a Phase 1 trial (NCT06736418) in small cell lung cancer and large cell neuroendocrine carcinoma under FDA Fast Track designation; a second program, ABD-320, targets 5T4. Abdera's product is a drug candidate, not software. It runs no developer program and publishes no API, developer portal, API reference, SDK, or machine-readable specification of any kind. As of 2026-09-06 the company's own corporate site at www.abderatx.com was additionally unreachable, returning a Flywheel "Unknown Domain" host error on every path behind a TLS certificate that expired on 2026-07-19.
Abdera Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Radiopharmaceuticals, and Oncology.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 1
The organization behind the API
Other 1
Properties that don't map to a standard resource type
Source (apis.yml)
Work with this as data
Every provider here is available over the APIs.io API and to AI agents over MCP.